Evidence map›Paper›PMID 42080115›Full record

ReviewAvicenna journal of medical biotechnology2026

HLA Type and the Effect of HLA Antibodies in Kidney, Liver, and Pancreas Transplantation: A Review.

Edalat Zarei, Jamshid Roozbeh, Hamed Nikoupour Deylami, Saman Nikeghbalian, Mahbube Ahrami, Farukhruzi Nasrollozoda, Ahmad Hashemzehi, Masoud Hashemzaei

Abstract readReview
In one paragraph

Review in Avicenna journal of medical biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Edalat ZareiShiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Jamshid RoozbehShiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Hamed Nikoupour DeylamiShiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Saman NikeghbalianShiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Mahbube AhramiShiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Farukhruzi NasrollozodaNational Scientific Center for Human Organs and Tissues Transplantation, State Medical University, Dushanbe, Republic of Tajikistan, Tajikistan.
Ahmad HashemzehiDepartment of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Masoud HashemzaeiPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Solid Organ Transplantation (SOT) has evolved from being an experimental procedure to a well-established therapeutic option for patients with end-stage organ failure. Among the most prevalent types of transplantation are liver, kidney, and pancreas transplants. Progress in surgical techniques and organ procurement has led to a decrease in complications, such as ischemic injury. Nevertheless, immune-mediated graft rejection continues to pose a significant challenge. The purpose of this review is to underscore the significance of Human Leukocyte Antigen (HLA) in the outcomes of SOT, particularly its critical role in donor-recipient matching, the risk of rejection, and the long-term survival of grafts. A comprehensive review of the relevant literature concerning the relationship between HLA and SOT was conducted, focusing on the function of Major Histocompatibility Complex (MHC) molecules, HLA typing, and the effects of HLA diversity on organ matching and clinical results. HLA typing serves as a fundamental element in assessing donor-recipient compatibility and minimizing the chances of graft rejection. The extensive polymorphism of HLA alleles, along with the existence of donor-specific antibodies, complicates the matching process, influences waiting periods, and impacts graft prognosis. Modulating HLA-mediated immune responses has the potential to enhance graft stability in liver, kidney, and pancreas transplantation. HLA molecules are crucial to the success of SOT. Ongoing clinical trials investigating novel immunosuppressive agents and HLA-targeted strategies may improve rejection management and long-term transplant outcomes. This review highlights the critical importance of HLA in liver, kidney, and pancreas transplantation.

Indexed as

AntigensKidneyLiverPancreasSolid organ transplantation

Identifiers

PMID42080115
PMCPMC13134671

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.